Qingdao Sino-cell Biomedicine Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2019-03-04
- Employees
- -
- Market Cap
- -
HS-IT101 Injection in the Treatment of Advanced Melanoma
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Qingdao Sino-Cell Biomedicine Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT06941818
- Locations
- 🇨🇳
Peking University Cancer Hospital, BeiJing, China
HS-IT201 Injection in the Treatment of Advanced Solid Tumors
Early Phase 1
Not yet recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: HS-IT201 Injection
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Lead Sponsor
- Qingdao Sino-Cell Biomedicine Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT06613152
HS-IT101 Injection in the Treatment of Advanced Solid Tumors
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Qingdao Sino-Cell Biomedicine Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT06342336
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath